K
KeyMed Biosciences Inc
HKEX:2162
KeyMed Biosciences Inc
HKEX:2162
Price:
53.8
HKD
6.64%
Market Cap:
HK$16.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
CN |
|
P
|
PALTAC Corp
TSE:8283
|
JP |
|
E
|
Enel Americas SA
SGO:ENELAM
|
CL |
|
D
|
Dongjin Semichem Co Ltd
KOSDAQ:005290
|
KR |
|
China Southern Power Grid Energy Efficiency&Clean Energy Co Ltd
SZSE:003035
|
CN |
|
A
|
AMTD Digital Inc
NYSE:HKD
|
SG |
|
Animalcare Group PLC
LSE:ANCR
|
UK |
|
C
|
Chularat Hospital PCL
SET:CHG
|
TH |
|
H
|
Hubei Guochuang Hi-tech Material Co Ltd
SZSE:002377
|
CN |
|
Pandox AB
STO:PNDX B
|
SE |
|
F
|
Ferrotec An Hui Technology Development Co Ltd
SZSE:301297
|
CN |
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
CN |
|
Sieyuan Electric Co Ltd
SZSE:002028
|
CN |
|
Jayride Group Ltd
ASX:JAY
|
AU |
|
C
|
Charan Insurance PCL
SET:CHARAN
|
TH |
|
TPI Triunfo Participacoes e Investimentos SA
BOVESPA:TPIS3
|
BR |
|
Balmer Lawrie and Company Ltd
NSE:BALMLAWRIE
|
IN |
Relative Value
The Relative Value of one KeyMed Biosciences Inc stock under the Base Case scenario is hidden HKD. Compared to the current market price of 53.8 HKD, KeyMed Biosciences Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KeyMed Biosciences Inc Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
KeyMed Biosciences Inc Competitors
KeyMed Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
K
|
KeyMed Biosciences Inc
HKEX:2162
|
16.1B HKD | 16.2 | -54.9 | -50 | -35.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.8B USD | 5.9 | 86.7 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.8B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.5 | 28.8 | 21.7 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.4 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.1 | 32.6 | 35.1 | 35.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
